222 related articles for article (PubMed ID: 14727465)
1. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behçet's disease.
Andonopoulos AP; Meimaris N; Daoussis D; Bounas A; Yiannopoulos G
Clin Exp Rheumatol; 2003; 21(4 Suppl 30):S57-8. PubMed ID: 14727465
[No Abstract] [Full Text] [Related]
2. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.
Licata G; Pinto A; Tuttolomondo A; Banco A; Ciccia F; Ferrante A; Triolo G
Ann Rheum Dis; 2003 Mar; 62(3):280-1. PubMed ID: 12594127
[No Abstract] [Full Text] [Related]
3. Remission of Behçet's syndrome with TNFalpha blocking treatment.
Rozenbaum M; Rosner I; Portnoy E
Ann Rheum Dis; 2002 Mar; 61(3):283-4. PubMed ID: 11830448
[No Abstract] [Full Text] [Related]
4. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
[No Abstract] [Full Text] [Related]
5. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behçet's disease.
Behrens F; Zollner T; Moeller B; Kaltwasser JP; Kaufmann R; Ochsendorf FR
Adv Exp Med Biol; 2003; 528():561-2. PubMed ID: 12918764
[No Abstract] [Full Text] [Related]
6. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
7. Infliximab in refractory uveitis due to Behçet's disease.
Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease.
Nakamura S; Ohno S
Int Ophthalmol Clin; 2005; 45(2):179-89. PubMed ID: 15791165
[No Abstract] [Full Text] [Related]
9. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy.
Boers M;
Arthritis Rheum; 2001 Nov; 44(11):2703-4. PubMed ID: 11710727
[No Abstract] [Full Text] [Related]
10. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis.
Arayssi T; Hamra R; Homeidan F; Uthman I; Awwad ST; Mroue K; Mansour W; Bashshur ZF
Clin Exp Rheumatol; 2005; 23(3):427. PubMed ID: 15971438
[No Abstract] [Full Text] [Related]
11. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease.
Rosenbaum JT
J Rheumatol; 2004 Jul; 31(7):1241-3. PubMed ID: 15229938
[No Abstract] [Full Text] [Related]
12. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
[No Abstract] [Full Text] [Related]
13. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction.
Vultaggio A; Matucci A; Nencini F; Pratesi S; Maggi E
Intern Emerg Med; 2012 Sep; 7 Suppl 2():S77-9. PubMed ID: 21544533
[No Abstract] [Full Text] [Related]
14. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab.
Conti F; Priori R; Chimenti MS; Coari G; Annovazzi A; Valesini G; Signore A
Arthritis Rheum; 2005 Apr; 52(4):1224-6. PubMed ID: 15818709
[TBL] [Abstract][Full Text] [Related]
16. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab.
Atzeni F; Leccese P; D'Angelo S; Sarzi-Puttini P; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S94. PubMed ID: 20868581
[No Abstract] [Full Text] [Related]
18. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease.
Triolo G; Vadalà M; Accardo-Palumbo A; Ferrante A; Ciccia F; Giardina E; Citarrella P; Lodato G; Licata G
Ann Rheum Dis; 2002 Jun; 61(6):560-1. PubMed ID: 12006336
[No Abstract] [Full Text] [Related]
19. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.
Goossens PH; Verburg RJ; Breedveld FC
Ann Rheum Dis; 2001 Jun; 60(6):637. PubMed ID: 11350856
[No Abstract] [Full Text] [Related]
20. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.
Ju JH; Kwok SK; Seo SH; Yoon CH; Kim HY; Park SH
Clin Rheumatol; 2007 Aug; 26(8):1383-5. PubMed ID: 17039261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
